EUCTR2022-002191-36-Outside-EU/EEA进行中（未招募）1 期
A Phase 1, Open-label, Randomized, Crossover, Bioavailability, Dose Proportionality, and Food Effect Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Shire
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- An understanding, ability, and willingness to fully comply with study procedures and restrictions.
- •- Ability to voluntarily provide written, signed, and dated (personally or via a legally-authorized representative) informed consent/and assent as applicable to participate in the study.
- •- Age 18-50 years, inclusive at the time of consent.
- •- Male, or non-pregnant, non-breastfeeding female who agrees to comply with any applicable contraceptive requirements of the protocol or females of non-childbearing potential.
- •- Healthy as determined by the investigator on the basis of screening evaluations.
- •- Hemoglobin for males greater than or equal to (> or =)135.0 gram per liter (g/L) and females > or = 120.0 g/L at screening and on Day -1.
- •- Body mass index (BMI) between 18.0 and 30.0 kilogram per meter square (kg/m2) inclusive with a body weight greater than (>) 50 kg (110 lbs).
- •- Ability to swallow a dose of investigational product.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 38
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- History of any hematological, hepatic, respiratory, cardiovascular, renal, neurological or psychiatric disease, gallbladder removal, or current recurrent disease that could affect the action, absorption, or disposition of the investigational product, or clinical or laboratory assessments.
- •- Current or relevant history of physical or psychiatric illness, any medical disorder that may require treatment or make the participant unlikely to fully complete the study, or any condition that presents undue risk from the investigational product or procedures.
- •- Known or suspected intolerance or hypersensitivity to the investigational product(s), closely-related compounds, or any of the stated ingredients.
- •- Significant illness, as judged by the investigator, within 2 weeks of the first dose of investigational product.
- •- Donation of blood or blood products (e.g., plasma or platelets) within 60 days prior to receiving the first dose of investigational product.
- •- Within 30 days prior to the first dose of investigational product:a) Have used an investigational product, b) Have been enrolled in a clinical study (including vaccine studies) that, in the investigator's opinion, may impact this study, c) Have had any substantial changes in eating habits, as assessed by the investigator.
- •- Confirmed systolic blood pressure >139 millimetre of mercury (mmHg) or < 89 mmHg, and diastolic blood pressure > 89 mmHg or < 49 mmHg.
- •- Twelve-lead ECG demonstrating QTc > 450 millisecond (msec).
- •- Known history of alcohol or other substance abuse within the last year.
- •- Male participants who consume more than 21 units of alcohol per week or 3 units per day. Female participants who consume more than 14 units of alcohol per week or 2 units per day.
- •- A positive screen for alcohol or drugs of abuse at screening or on Day -1 of Treatment Period.
- •- A positive human immunodeficiency virus (HIV), HBsAg, or Hepatitis C virus (HCV) antibody screen.
- •- Use of tobacco in any form (e.g., smoking or chewing) or other nicotine-containing products in any form (e.g., gum, patch).
- •- Routine consumption of more than 2 units of caffeine per day or participants who experience caffeine withdrawal headaches.
- •- Prior screen failure, randomization, enrollment, participation in this study or participation in Part 1 of this study.
- •- Current use of any prescription medication with the exception of hormonal replacement therapy. (Current use is defined as use within 30 days of the first dose of investigational product.) Current use of any over the counter medication (including herbal, or homeopathic preparations) within 14 days of the first dose of investigational product.
- •- Current use of antacids and H2 antagonists.
- •- Ingestion of known CYP3A modulators within 7 days of Day 1, Period 1.
- •- Inability or unwillingness to consume 100 percent of high-fat meal in Part 2 (including participants with lactose or gluten intolerance).
- •- History of oral/nasal cavity infections, gastroesophageal reflux, asthma treatment with albuterol, zinc supplementation.
- •- Participants with dry mouth syndrome or burning mouth syndrome or menopausal women suffering from dysgeusia.
研究者
相似试验
已完成
不适用
A phase I open-label, balanced, randomized, crossover, three-groups, three-treatments, three-period, pharmacokinetic study of intranasal testosterone gel administration to healthy, adult, male subjectshypogonadismlow testosterone levels in men10014701NL-OMON36048Trimel BioPharma SR15
已完成
不适用
An open-label, randomized, crossover, phase 1 study to evaluate bioequivalence and relative bioavailability between JZP-507 commercial scale and pilot oral solutions in healthy subjectsnarcolepsysleeping disorder10040998NL-OMON44398Jazz Pharmaceuticals, inc.30
尚未招募
不适用
A Phase I, open-label, randomized, 2-way crossover trial in 40 healthy subjects to investigate the potential pharmacokinetic interactions between telaprevir and darunavir/ritonavir and between telaprevir and fosamprenavir/ritonavir at steady-statehepatitis C / liver disease10047438NL-OMON32330TIBOTEC PHARMACEUTICALS In Nederland vertegenwoordigd door Janssen-Cilag B.V. afdeling GCO40
尚未招募
不适用
A Phase I, open-label, randomized, 2-way crossover trial in 2 parallel panels of 20 healthy subjects each to investigate the pharmacokinetic interaction between lopinavir/ritonavir (LPV/rtv) and telaprevir, and between atazanavir/ritonavir (ATV/rtv) and telaprevir, all at steady-state.NL-OMON30839Tibotec Pharmaceuticals40
已完成
不适用
A Phase I, open-label, randomized, two-way crossover study to investigate the effects of morning versus evening repeated dosing on the pharmacokinetics of the combination of GLPG3067, GLPG2222 and GLPG2737 in healthy female subjects.MucoviscidosisCystic FibrosisNL-OMON44378Galapagos N.V.10